Glaukos (NYSE:GKOS) Releases Earnings Results, Misses Estimates By $0.02 EPS

Glaukos (NYSE:GKOS - Get Free Report) issued its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02), Zacks reports. The business had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Glaukos updated its FY 2025 guidance to EPS.

Glaukos Stock Performance

Glaukos stock traded down $31.33 during mid-day trading on Friday, hitting $126.03. 4,139,906 shares of the company's stock traded hands, compared to its average volume of 515,602. The firm has a 50 day simple moving average of $152.75 and a two-hundred day simple moving average of $139.41. Glaukos has a fifty-two week low of $83.90 and a fifty-two week high of $163.71. The stock has a market cap of $6.95 billion, a price-to-earnings ratio of -43.91 and a beta of 1.04. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Analyst Upgrades and Downgrades

GKOS has been the subject of several research reports. Morgan Stanley cut shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price target for the company. in a research note on Monday, December 2nd. Stephens raised shares of Glaukos to a "strong-buy" rating in a research note on Monday, December 2nd. Piper Sandler reaffirmed an "overweight" rating and set a $180.00 price target (up from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Mizuho raised Glaukos from a "neutral" rating to an "outperform" rating and increased their price objective for the company from $140.00 to $200.00 in a report on Wednesday. Finally, UBS Group initiated coverage on Glaukos in a report on Friday, December 6th. They issued a "buy" rating and a $182.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $163.25.

Insider Buying and Selling at Glaukos

In other news, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction on Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the sale, the chief operating officer now owns 102,169 shares of the company's stock, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total value of $288,020.00. Following the sale, the director now directly owns 32,336 shares of the company's stock, valued at $4,656,707.36. This represents a 5.82 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,744 shares of company stock valued at $2,792,151 in the last quarter. 6.40% of the stock is currently owned by insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.